Zymeworks Inc Stock News

Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.

Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials a

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape

Zymeworks (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape

Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

In the stock markets, fortunes rise and fall on the tide of hype and advancements, with the tech sector impacted the most. As the world is in the middle of a decade, the stage is set for the listed te

Zymeworks Inc. (NASDAQ:ZYME ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $4.65 per share a year ago.

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) --  Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biothera

Zymeworks' stock has increased by 67% since September, driven by developments in the antibody-drug conjugate sector. The company's lead asset, zanidatamab, is being developed for the treatment of firs

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu

The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are

Investing in small-cap stocks offers multiple advantages for those looking to diversify their portfolios with potential high-growth opportunities efficiently. Small-cap stocks strike a unique balance